Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $4.3 million.

  • Enanta Pharmaceuticals' Prepaid Assets fell 5935.98% to $4.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.3 million, marking a year-over-year decrease of 5935.98%. This contributed to the annual value of $8.6 million for FY2025, which is 3079.84% down from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Prepaid Assets stood at $4.3 million, which was down 5935.98% from $8.6 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Prepaid Assets ranged from a high of $32.1 million in Q1 2021 and a low of $4.3 million during Q4 2025
  • In the last 5 years, Enanta Pharmaceuticals' Prepaid Assets had a median value of $12.8 million in 2023 and averaged $13.3 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Prepaid Assets soared by 6203.68% in 2021 and then tumbled by 5935.98% in 2025.
  • Enanta Pharmaceuticals' Prepaid Assets (Quarter) stood at $11.5 million in 2021, then surged by 55.97% to $17.9 million in 2022, then fell by 26.2% to $13.2 million in 2023, then fell by 19.34% to $10.7 million in 2024, then tumbled by 59.36% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q4 2025, $8.6 million for Q3 2025, and $10.2 million during Q2 2025.